We’re closer than ever, but not there yet. For the first time, a small number of patients with severe autoimmune diseases have achieved what researchers call a “functional cure,” meaning complete remission lasting at least 12 months without any immunosuppressive medication, with normal lab markers and no new organ damage. These results come from experimental therapies, mostly in small trials, and they don’t yet apply to the roughly 8% to 10% of the global population living with an autoimmune condition. But the trajectory has shifted. The conversation in medicine has moved from “how do we manage this for life” to “can we reset the immune system and walk away.”
What “Curing” an Autoimmune Disease Actually Means
Autoimmune diseases arise when the immune system attacks the body’s own tissues. Because the underlying genetic susceptibility never disappears, most researchers avoid the word “cure” in an absolute sense. Instead, they use a layered framework. “Clinical remission” means no active symptoms. “Complete remission” adds normal lab results, including autoantibody levels. “Drug-free remission” means staying in complete remission after stopping all medication. And a “functional cure” requires all of this to hold for at least 12 months with no new progressive damage.
That last category is the meaningful one. A person who meets the criteria for a functional cure lives without symptoms, takes no immunosuppressive drugs, and shows no signs of the disease on blood tests. They might still carry the genetic predisposition for relapse, but their immune system has effectively been retrained. Five years ago, this outcome was nearly unheard of outside of a few transplant cases. Today, multiple experimental approaches are producing it.
CAR-T Cell Therapy: The Most Dramatic Results So Far
The biggest leap forward has come from CAR-T cell therapy, a technique originally developed for blood cancers. It works by extracting a patient’s own immune cells, engineering them to target and destroy B cells (the immune cells that produce the antibodies attacking the body), and infusing them back. Once the rogue B cells are wiped out, the immune system rebuilds from scratch, ideally without the autoimmune programming.
A landmark series from Germany treated 15 patients with severe lupus, inflammatory muscle disease, or systemic sclerosis. All showed significant improvement in disease activity. None required further immunosuppressive therapy at a median follow-up of 15 months, and one patient has remained drug-free for over three years. In lupus patients specifically, the destructive antibodies dropped and complement proteins (markers of immune health that are typically depleted in active lupus) returned to normal levels. Side effects were mild: no severe immune reactions or neurological toxicity, though three patients needed treatment for low-grade inflammatory responses and one was hospitalized for pneumonia.
A separate trial tested a next-generation version of CAR-T that targets two types of immune cells simultaneously. Of 13 lupus patients treated, 9 achieved complete symptom-free and medication-free remission, and 10 of 13 saw significant improvement in kidney function, a critical outcome since lupus nephritis is one of the disease’s most dangerous complications.
These numbers are remarkable, but context matters. These are small trials. The patients were carefully selected. Manufacturing CAR-T cells is expensive and time-consuming, currently requiring a custom product for each individual. And we don’t yet know how long remissions will last in most patients. Still, the signal is strong enough that dozens of larger trials are now underway worldwide.
Stem Cell Transplants: A Proven but Intensive Option
Before CAR-T entered the picture, hematopoietic stem cell transplantation (HSCT) was the main approach to resetting the immune system. The process involves using chemotherapy to destroy the existing immune system, then rebuilding it from the patient’s own stem cells. It’s essentially a hard reboot.
For multiple sclerosis, about 70% of patients who undergo HSCT experience disease stabilization or improvement lasting at least three years. For systemic sclerosis (scleroderma), the five-year progression-free survival rate exceeds 50%. These are meaningful results for diseases that otherwise progress relentlessly.
The trade-off is intensity. HSCT requires hospitalization, carries a real risk of serious infection during the period when the immune system is suppressed, and historically has had a small but non-trivial mortality rate. It’s generally reserved for patients with aggressive disease who haven’t responded to standard treatments. CAR-T therapy, which doesn’t require full immune destruction beforehand, may eventually replace HSCT for many autoimmune conditions, but transplants remain the approach with the longest track record.
Inverse Vaccines and Tolerance Therapy
CAR-T and stem cell transplants are powerful but blunt. They wipe out large portions of the immune system. The holy grail of autoimmune treatment is something far more precise: retraining just the immune cells responsible for the attack while leaving the rest of the immune system intact.
This is the idea behind antigen-specific immunotherapy, sometimes called “inverse vaccines.” The concept is to introduce the specific protein the immune system is mistakenly attacking, delivered in a way that teaches immune cells to tolerate it rather than fight it. There are several mechanisms by which this can work. The offending immune cells can be rendered unresponsive (a state called anergy), actively killed off through programmed cell death, or overridden by regulatory cells that the therapy stimulates. These regulatory cells travel to the site of autoimmune damage and release chemical signals that calm the broader immune attack, a process researchers call “bystander suppression.”
This approach has shown proof of concept in animal models and early human trials, but it hasn’t yet produced the kind of clean remission data seen with CAR-T. The challenge is precision: each autoimmune disease targets different proteins, and even within a single disease, different patients may have immune responses directed at different targets. Building a tolerance therapy that works broadly is a harder engineering problem than building one that works in a controlled lab setting. Several companies are in early clinical trials, with results expected over the next few years.
Stem Cells for Type 1 Diabetes
Type 1 diabetes sits in a unique position among autoimmune diseases because the damage is highly specific: the immune system destroys insulin-producing cells in the pancreas. If you can replace those cells and prevent the immune system from destroying them again, you’ve functionally cured the disease.
A recent trial did exactly that. Researchers implanted lab-grown insulin-producing cells derived from stem cells into 12 patients with type 1 diabetes. After one year, 10 of the 12 (83%) had achieved insulin independence, meaning they no longer needed insulin injections. Published in the New England Journal of Medicine, these results represent one of the most concrete examples of a functional cure for any autoimmune disease, though patients still require immune-suppressing drugs to protect the transplanted cells. Solving that last piece, either through better cell engineering or tolerance induction, would make the approach truly curative without ongoing treatment.
Targeting the Trigger: EBV and Multiple Sclerosis
One of the most exciting shifts in autoimmune research is the move toward prevention. A growing body of evidence links Epstein-Barr virus (EBV), which infects more than 90% of adults, to the development of multiple sclerosis. The virus doesn’t cause MS in most people, but it appears to be a necessary trigger in those who are genetically susceptible.
A Phase 2 clinical trial is now underway in the UK testing whether a vaccine against EBV can help treat MS by training the immune system to keep the virus suppressed. The trial will run approximately 2.5 years and is evaluating both safety and the vaccine’s effect on new MS disease activity. If vaccination can reduce or prevent MS onset, it would represent a fundamentally different kind of cure: one that stops the disease before it starts. Population-wide EBV vaccination for MS prevention is still years away from being validated, but the trial marks the first serious test of the concept.
The Microbiome Angle
Fecal microbiota transplant (FMT), which replaces a patient’s gut bacteria with those from a healthy donor, has shown modest results in ulcerative colitis. Across nine randomized controlled trials, 32.8% of patients receiving FMT achieved clinical remission compared to 16.3% in control groups. That’s roughly double the remission rate, with a low risk of serious side effects. However, FMT has been better at inducing remission than maintaining it, and its role in other autoimmune diseases remains largely unproven. Gut bacteria clearly influence immune function, but manipulating the microbiome as a standalone treatment is still early-stage for most conditions.
Where Things Stand Right Now
The global prevalence of autoimmune diseases has nearly doubled from 1990 to 2021, making effective treatments more urgent than ever. Most patients today are still managed with drugs that broadly suppress the immune system, reducing symptoms but increasing infection risk and requiring lifelong use. The FDA continues to approve new options along these lines: 2024 saw approvals for primary biliary cholangitis, expanded use of existing lupus treatments for children, and a subcutaneous version of an MS therapy that allows at-home administration. These improve quality of life, but they’re not cures.
The experimental therapies producing drug-free remission, particularly CAR-T, face three practical hurdles before they can reach most patients. Cost is the first: current CAR-T manufacturing runs into six figures per patient. Scale is the second: producing individualized cell therapies for millions of people requires manufacturing infrastructure that doesn’t yet exist. And durability is the third: the longest follow-up data for autoimmune CAR-T is still only a few years. We don’t yet know whether these remissions will hold for a decade or a lifetime.
The honest answer is that functional cures already exist for a small number of patients with specific autoimmune diseases, and the next five to ten years will determine whether those results can be made cheaper, more durable, and available at scale. We are not at the finish line, but for the first time, the finish line is visible.